# Rezafungin (Rezzayo)

> Once-weekly echinocandin for candidemia and invasive candidiasis.

Source: https://peptides.cafe/peptide/rezafungin
Category: Echinocandin · Antifungal
Tag: FDA-Approved · Antifungal

## Mechanism
Next-generation echinocandin structurally related to anidulafungin with enhanced stability, inhibiting β-(1,3)-D-glucan synthase; long half-life permits once-weekly IV dosing.

## Research areas
- Candidemia
- Invasive candidiasis

## Common research protocols
- Weekly IV: 400 mg IV week 1, then 200 mg IV weekly.

## Study summaries
- "ReSTORE trial" — Lancet (2023): Non-inferior to caspofungin for candidemia/invasive candidiasis.

## Considerations
- FDA-approved (2023).
- Infusion reactions and photosensitivity reported.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.